Jefferies gives Endo Pharma buy rating

Endo Pharmaceuticals Inc. was given a buy rating and a target of $29.12 by Jefferies & Co., Inc. analyst David Windley on estimates that, driven by strong Lidoderm sales, the company should beat consensus revenue forecasts. Lidoderm's 2005 sales are expected to exceed management's guidance of $390 million to $400 million. Shares of the Chadds Ford, Pa., specialty pharmaceutical company were down 97 cents, or 3.33%, at $28.15 on volume of 4,534,716 shares versus the three-month running average of 1,193,480 shares. (Nasdaq: EDNP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.